PO.CL04.01 · 临床研究
在女性纵向TLC队列研究中睡眠与身体功能之间的关联
The association between sleep and physical function in the longitudinal TLC cohort study of women
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:睡眠障碍(如失眠)在绝经后女性中很常见,可能对身体功能产生负面影响。这些障碍在乳腺癌幸存者中比在一般女性人群中更为频繁。关于睡眠如何影响老年乳腺癌患者身体功能的数据有限。我们分析了睡眠质量是否影响一年随访时的身体功能,以及反之亦然。
方法:数据来自“思考与带癌生活”(Thinking and Living with Cancer)研究,这是一项多中心纵向研究,纳入年龄60岁及以上、新近确诊乳腺癌的女性以及频率匹配的非癌症对照。参与者每年随访一次,最长随访五年。睡眠质量采用PSQI评估(范围0-21;分值越高表示睡眠质量越差);身体功能采用SF-12身体成分评分(PCS)和计时起立行走测试(TUG)测量。SF-12 PCS下降3-5分被视为具有临床意义。随机截距交叉滞后面板模型(RI-CLPM)使用来自767名女性(339名对照和428名幸存者)的数据分析关联,并对年龄、种族、合并症和招募地点进行了校正。
结果:参与者平均年龄为69.5岁(幸存者70.0岁,对照69.3岁)。睡眠中断在基线时在幸存者中更为常见(PSQI高于5:43.9%对29.0%;p<0.001),且在随访期间仍更为普遍。幸存者表现出具有临床意义的PCS下降(第1年-2.8分;两年内-3.0分),而对照仅有小幅、渐进、无临床意义的下降(约-0.5分/年)。TUG没有明确的轨迹,RI-CLPM未显示PSQI与TUG之间存在显著关联。
在幸存者中,前三年内PSQI每高出1分预示随后年度访视时SF-12 PCS降低0.4-0.5分(P<0.001),至第4年降至0.3分(P=0.03)。在对照中,效应最初较小(-0.25分,p=0.10),但从第2年到第5年,PSQI每增加1分预示SF-12 PCS降低0.4-0.65分(p=0.01至<0.001)。
对于幸存者和对照而言,假设PCS随PSQI每增加1分下降0.4分,则女性PSQI相对于其通常水平恶化10分,预计对应于一年后SF-12 PCS降低约4分。
结论:睡眠中断与幸存者和对照随后身体功能的下降相关,随着睡眠质量恶化,这种下降可达到具有临床意义的幅度。鉴于乳腺癌幸存者中睡眠问题的高患病率,对睡眠障碍进行常规监测和及时干预可能有助于在不断增长的老年癌症幸存者人群中保持功能,尤其是在治疗后的早期阶段。
本项工作是在整个TLC-Age研究团队的贡献下完成的。
查看英文原文 English abstract
Background: Sleep disturbances, such as insomnia, are common in postmenopausal women and may negatively impact physical functioning. These disturbances are more frequent in breast cancer survivors than in the general female population. Limited data exist on how sleep affects physical function in older breast cancer patients. We analyzed whether sleep quality influences physical function at a one-year follow-up, and vice versa.
Methods: Data were from the Thinking and Living with Cancer study, a multicenter, longitudinal study involving women aged 60 and older, newly diagnosed with breast cancer and frequency-matched non-cancer controls. Participants were followed annually for up to five years. Sleep quality was assessed with the PSQI (range 0-21; higher scores indicate poorer sleep quality); physical functioning was measured by the SF-12 physical component score (PCS) and the Timed Up and Go (TUG). A 3-5 point SF-12 PCS decline was considered clinically meaningful. Random intercept cross-lag panel models (RI-CLPM) analyzed associations using data from 767 women (339 controls and 428 survivors), adjusting for age, race, comorbidities, and recruitment site.
Results: Mean age of participants was 69.5 years (70.0 in survivors vs. 69.3 in controls). Disrupted sleep was more common among survivors at baseline (PSQI above 5: 43.9% vs. 29.0%; p less than 0.001) and remained more prevalent during follow-up. Survivors showed a clinically meaningful decline in PCS (-2.8 points in year 1; -3.0 points over two years), whereas controls had a small, gradual, non-clinically meaningful decline (≈ -0.5 points/year). There was no clear trajectory for TUG, and the RI-CLPM revealed no significant associations between PSQI and TUG.
In survivors, each 1-point higher PSQI predicted 0.4-0.5 points (P less than 0.001) lower SF-12 PCS at the subsequent annual visit during the first three years, decreasing to 0.3 points by year 4 (P = 0.03). Among controls, effects were small initially (-0.25 points, p = 0.10) but from years 2 to 5 a 1-point PSQI increase predicted 0.4-0.65 points lower SF-12 PCS (p = 0.01 to less than 0.001).
For both survivors and controls, a 10-point worsening in a woman's PSQI relative to her usual level would be expected to correspond to about a 4-point lower SF-12 PCS one year later, assuming a 0.4-point decrease in PCS per 1-point increase in PSQI.
Conclusion: Sleep disruption is associated with subsequent declines in physical function among survivors and controls, which can reach clinically meaningful magnitudes as sleep quality worsens. Given the high prevalence of sleep problems among breast cancer survivors, routine monitoring for sleep disturbances and timely intervention may help preserve function in the growing population of older cancer survivors, particularly in the early years following treatment.
This work was conducted with contributions from the entire TLC-Age research team.
利益披露 Disclosure
C. Kusters, None..
W. Zhai, None..
X. Zhou, None..
Z. Nakamura, None..
J. Ahn, None..
A. L. Artese, None..
D. Graham, None..
C. Casagrande, None..
K. van Dyk, None..
T. A. Ahles, None..
T. N. Bethea, None..
H. Cohen, None..
C. Isaacs, None..
B. McDonald, None..
S. Patel, None..
J. C. Root, None..
A. Saykin, None..
B. Small, None.
J. S. Mandelblatt,
Georgetown University/Cantex Pharmaceuticals Other, She has a pending invention patent application (PCT/US2022/028741) filed by Georgetown University entitled “Use of RAGE inhibitors to Treat Cancer-Related Cognitive Decline” and licensed to Cantex Pharmaceuticals. She has waived rights and will not receive any remuneration, consideration, or revenue generated from this license or the patents and patent applications licensed thereunder.